Member Directory

Cambridge Employment Law LLP is a boutique employment law practice, advising both employers and employees. Our size and the specialist nature of our practice mean that you will have a personal relationship with a lawyer who understands your business and cares about its success. Our advice is always commercial and pragmatic, based on our lawyers' many years of experience and technical expertise. Eleanor Freeman has a particular interest in the biomedical sector. Her familiarity with the common challenges facing start-ups and high growth companies is balanced with significant experience representing global pharmaceuticals in all employment-related matters.

Cambridge Enterprise is responsible for the commercialisation of intellectual property from the University of Cambridge. We work with members of the university to help them commercialise their research and provide consultancy services to the industry. We give vital support to early-stage companies, helping them develop innovative technology ventures which benefit society and the wider economy.

Cambridge Innovation Capital (“CIC”) combines a unique relationship with the University of Cambridge and deep financial and industry links. CIC invests in rapidly growing intellectual property rich companies in the Cambridge Cluster. . . The company is committed to building leading businesses from brilliant technologies - with the support of some of the most influential figures in the sector and a patient capital structure.

Cambridge Network is a membership organisation focused on bringing people together for shared success. With talent and expertise in abundance in this vibrant, world-renowned high technology cluster we want to attract people to join us and to promote the best that Cambridge can offer. The network works with start-ups, SMEs and multinationals to collaborate for shared success and to be better by: shared learning opportunities; operating a varied events schedule; offering as a channel for members to promote themselves, their products/services and activities; working together to attract and retain talented employees; and providing a directory resource of business and academia.

Cancer Research Horizons is the innovation engine of Cancer Research UK – the world’s largest charitable funder of cancer research. We bring together the best minds, bold ideas, and the right partners to bridge the gap between academic research and taking drugs to market. We focus on the tougher, more profound ideas that can lead to true innovation, translating them into effective treatments and diagnostics for cancer patients.

To date we’ve played an instrumental role in forming over 70 startup companies. We’ve helped bring 11 cancer drugs to market, borne out of Cancer Research UK’s pioneering research. Through these drugs, we have enabled in excess of 6 million courses of treatment for cancer patients worldwide.

With access to Cancer Research UK’s network of 4,000 exceptional researchers, and over £400m of annual research spend, we’re a powerful partner in the fight to conquer cancer. By uniting our commercial partnerships and therapeutic innovation capabilities, Cancer Research Horizons is uniquely placed to support translational funding, entrepreneurial development, licensing and collaboration, start-up creation, and offer a full spectrum of drug discovery and clinical capabilities.

Every penny we make goes back into funding the next bold steps, to help bring forward the day when all cancers and conquered.

Cancer Research Technology (CRT) is dedicated to advancing discoveries to beat cancer. We develop and commercialise exciting new discoveries in cancer research, working closely with leading clinical and academic institutions, pharmaceutical companies and biotechs worldwide. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. . . CRT is owned by Cancer Research UK, the world’s largest charitable funder of cancer research and we’re uniquely placed to capitalise on the research and connections of our parent organisation.

Carocell Bio are developing novel peptides to more safely and effectively treat inflammatory diseases.